Since 01/10/2013 : Researcher CR1, UMR 7292 (Tours, France). Fields : Therapeutic Monoclonal antibodies, Oncology, Pharmacokinetics and Modeling
2012-2013 : Researcher CR2, Inserm UMR S 968, Institut de la Vision (Paris, France). Fields : Age-related macular degeneration, Choroidal neovascularization and Inflammation
2009-2012: Researcher CR2, Inserm UMR S 872, Centre de Recherche des Cordeliers (Paris, France). Fields : Age-related macular degeneration, Inflammation and Chemokines
2006-2009 : Post-doctoral position in Ophtalmology, Inserm UMR S 872, Centre de Recherche des Cordeliers (Paris, France). Fields : Age-related macular degeneration and Therapeutic tools
2001-2005 : PhD in Life and Health Sciences (Toxicology) with honours, Inserm U651, University of Paris XII (Créteil, France). Fields : Acute lung injury, Repair, Growth factors and Endothelial progenitors cells
2000-2001 : Master in Toxicology with honours, University of Paris V Descartes (Paris, France).
The goal of the team is to understand how genetic and non-genetic variations translate into variable clinical responses to monoclonal antibodies in treated patients. Our general aim is to fill in the gap between genetics and clinical responses by establishing precise genotype-phenotype relationships for therapeutic antibody elimination and distribution (pharmacokinetics, PK) and mechanisms of action (pharmacodynamics, PD).
• Pharmacokinetic and pharmacokinetic-pharmacodynamic (PK-PD) modelling of therapeutic monoclonal antibodies in human and in preclinical studies.
• Pharmacogenetics and genotype-phenotype relationships of therapeutic antibodies. In vitro and ex vivo cellular models, clinical studies in treated patients.
• Analysis of role of Fc-gamma-receptors and of FcRn in elimination and distribution of antibodies (pharmacokinetics) and in concentration-effect relationships in vivo (PK-PD).